Non-Invasive Prenatal Testing Market In United States To Expand Exponentially Through 2028

June 17, 2022


According to the market analysis report titled ‘Non-Invasive Prenatal Testing Market Research and Outlook, 2021 - Trends, Growth Opportunities, Competitive Analysis and Forecasts to 2028’, available with MarketStudyReport, non-invasive prenatal testing (NIPT) market U.S. is anticipated to surge at a robust pace and reach USD 2.5 billion by 2028.


Rising income levels, increasing frequency of chromosomal aneuploidies in the fetus, proliferation of advanced prenatal testing procedures, and growing inclination towards non-invasive methodologies over the invasive counterparts are the key factors that are fueling non-invasive prenatal testing (NIPT) market growth in United States.


Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4132710/   


Besides, favorable reimbursement policies and ACOG (American College of Obstetricians and Gynecologists) guidelines that encourage NIPT testing for all pregnancies regardless of the risk involved, are bound to aid in broadening the expanse of the market.


Apart from growth drivers and opportunities, the research literature also sheds light on current and upcoming challenges in the business sphere, while also divulging solutions. It also considers the market augmentation history, as well as current trends, to produce reliable estimates regarding revenue inflow and demand over 2015-2028. Information about volume of NIPT tests conducted, revenue shares, and future growth potential is also given.


Non-invasive prenatal testing market report also provides a comprehensive analysis on major partnership and collaboration deals, mergers and acquisitions, capital investments, distribution channels, and licensing agreements, thereby enabling the stakeholders to make informed decisions and reap maximum profits.


Speaking of the competitive landscape, reputed companies like Ariosa Diagnostics (Roche), Natera, Inc., Agilent Technologies, Inc., Illumina, Inc., PerkinElmer, Inc., GenPath, Inc., Myriad Genetics, Inc., Yourgene Health, Integrated Genetics (Labcorp), Centogene US LLC, Quest Diagnostics, Inc., Invitae Corporation, and Progenity, Inc. are thoroughly analyzed in the report.


The aforementioned players are assessed with respect to company overview, recent developments, and NIPT test portfolios to gauge their impact on the overall functioning of the non-invasive prenatal testing market during the analysis timeframe of 2021-2028. 

Chat with us